Drugs / SAL-0951
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT06720025 | Sep 2023 → Jun 2024 | anemia | Shenzhen Salubris Pharmaceuticals Co., Ltd. | Completed | No outcome recorded |
| Phase 3 | NCT06016036 | Dec 2020 → Oct 2021 | aregenerative anemia | Shenzhen Salubris Pharmaceuticals Co., Ltd. | Completed | No outcome recorded |
| Phase 3 | NCT06720233 | Feb 2002 → Oct 2024 | anemia | Shenzhen Salubris Pharmaceuticals Co., Ltd. | Completed | No outcome recorded |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SAL-0951 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06720025 ↗ |